Overview

Lybrido for Female Sexual Dysfunction

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The Lybrido study is a double-blind, randomized, placebo-controlled study with a 4-week baseline establishment period, 16 week treatment period and a follow up period for a total of 26 weeks on study. Subjects are randomly to one of seven treatment arms. The study investigates the effective dose of Lybrido in increasing the number of satisfactory sexual episodes in the domestic setting in 210 healthy female subjects with hypoactive sexual desire disorder and low sensitivity for sexual cues (30 subjects per group).
Phase:
Phase 2
Details
Lead Sponsor:
Emotional Brain NY Inc.
Treatments:
Methyltestosterone
Sildenafil Citrate
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate